首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Use of Molecular and Reference Susceptibility Testing Methods in a Multicenter Evaluation of MicroScan Dried Overnight Gram-Positive MIC Panels for Detection of Vancomycin and High-Level Aminoglycoside Resistances in Enterococci
【2h】

Use of Molecular and Reference Susceptibility Testing Methods in a Multicenter Evaluation of MicroScan Dried Overnight Gram-Positive MIC Panels for Detection of Vancomycin and High-Level Aminoglycoside Resistances in Enterococci

机译:分子和参考药敏试验方法在MicroScan干隔夜革兰氏阳性MIC板的多中心评估中的应用以检测万古霉素和肠球菌中的高水平氨基糖苷抗性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Modified MicroScan gram-positive MIC no. 8 panels (PM-8) were analyzed for their improved ability to detect vancomycin resistance (VR) and high-level aminoglycoside resistance (HLAR) in enterococci. A validation study design that utilized selected challenge strains, recent clinical isolates, and reproducibility experiments in a multicenter format was selected. Three independent medical centers compared the commercial panels to reference broth microdilution panels (RBM) and Synergy Quad Agar (QA). Resistance was verified by demonstration of VR and HLAR genes by PCR tests. The study was conducted in three phases. (i) In the challenge phase (CP), two well-characterized sets of enterococci were obtained from the Centers for Disease Control and Prevention; one set contained 50 isolates for VR testing and one contained 48 isolates for HLAR testing. In addition, a set of 47 well-characterized isolates representing diverse geographic areas, obtained from earlier national surveillance studies, was tested at the University of Iowa College of Medicine (UICM). (ii) In the efficacy phase (EP), each laboratory tested 50 recent, unique clinical isolates by all methods. (iii) In the reproducibility Phase (RP), each laboratory tested the same 10 strains by all methods in triplicate on three separate days. All isolates from the EP were sent to the UICM for molecular characterization of vanA, -B, -C1, -C2–3, and HLAR genes. In the CP, the ranking of test methods by error rates (in parentheses; very major and major errors combined, versus PCR results) were as follows: for high-level streptomycin resistance (HLSR), QA (12.0%) > PM-8 (5.2%) > RBM (1.6%); for high-level gentamicin resistance (HLGR), RBM (3.7%) > PM-8 (3.1%) > QA (2.6%); and for VR, RBM = QA (3.0%) > PM-8 (1.2%). In the EP, agreement between all methods and the reference PCR result was 98.0% for HLSR, 99.3% for HLGR, and 98.6% for VR. In the RP, the percentages of results ± 1 log2 dilution of the all-participant mode were as follows: for VR, 100% (PM-8), 98.9% (QA), and 90.0% (RBM); for HLSR, 99.6% (RBM), 98.5% (PM-8), and 82.2% (QA); and for HLGR, 99.6% (RBM), 99.3% (PM-8), and 98.1% (QA). The ability of the PM-8 to detect VR and HLAR in enterococci was comparable to those for reference susceptibility and molecular PCR methods and was considered acceptable for routine clinical laboratory use.
机译:修改后的MicroScan革兰氏阳性MIC号分析了8个小组(PM-8)改善了检测肠球菌中万古霉素抗性(VR)和高水平氨基糖苷抗性(HLAR)的能力。选择了一种验证研究设计,该设计利用了选定的挑战菌株,最新的临床分离株以及多中心形式的可再现性实验。三个独立的医疗中心将商业小组与参考肉汤微稀释小组(RBM)和Synergy Quad Agar(QA)进行了比较。通过PCR测试证实VR和HLAR基因证实了抗性。该研究分三个阶段进行。 (i)在挑战阶段,从疾病控制和预防中心获得了两套特征明确的肠球菌;一组包含用于VR测试的50个分离株,一组包含用于HLAR测试的48个分离株。此外,在爱荷华大学医学院(UICM)对来自早期国家监测研究的47个特征明确的代表不同地理区域的分离株进行了测试。 (ii)在功效阶段(EP),每个实验室通过所有方法测试了50种近期独特的临床分离株。 (iii)在可重复性阶段(RP),每个实验室通过所有方法分别在三天中一式三份地测试了相同的10个菌株。所有来自EP的分离株都被送到UICM进行vanA,-B,-C1,-C2-3和HLAR基因的分子表征。在CP中,通过错误率对测试方法的排名(括号中;非常主要和主要错误相加,相对于PCR结果)如下:对于高链霉素抗性(HLSR),QA(12.0%)> PM-8 (5.2%)> RBM(1.6%);对于高水平的庆大霉素耐药性,RBM(3.7%)> PM-8(3.1%)> QA(2.6%);对于VR,RBM ​​=质量检查(3.0%)> PM-8(1.2%)。在EP中,所有方法与参考PCR结果之间的一致性对于HLSR为98.0%,对于HLGR为99.3%,对于VR为98.6%。在RP中,全参与模式的结果百分比±1 log2稀释如下:对于VR,分别为100%(PM-8),98.9%(QA)和90.0%(RBM); HLSR分别为99.6%(RBM),98.5%(PM-8)和82.2%(QA); HLGR分别为99.6%(RBM),99.3%(PM-8)和98.1%(QA)。 PM-8检测肠球菌中VR和HLAR的能力可与参考药敏性和分子PCR方法相媲美,被认为可用于常规临床实验室。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号